Molecule Information

General Information of the Molecule (ID: Mol02110)

• Name: Oleandomycin glycosyltransferase oleD (OLED) ,Actinomycetia
• Synonyms: OLED
• Molecule Type: Protein
• Gene Name: OLED

Kingdom: N.A.
Phylum: Actinobacteria
Class: .
Order: .
Family: .
Genus: .
Species: Actinomycetia

Type(s) of Resistant Mechanism of This Molecule

  DISM: Drug Inactivation by Structure Modification

Drug Resistance Data Categorized by Drug

Investigative Drug(s) 1 drug(s) in total

Midecamycin

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Drug Inactivation by Structure Modification (DISM)

Disease Class: Pseudomonas aeruginosa infection [ICD-11: 1A00-1C4Z] [1]

• Resistant Disease: Pseudomonas aeruginosa infection [ICD-11: 1A00-1C4Z]
• Resistant Drug: Midecamycin
• Molecule Alteration: Expression; Acquired
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: Prostate cancer tissue; N.A.
• Experiment for Molecule Alteration: SDS-PAGE analysis
• Experiment for Drug Resistance: Broth microdilution antifungal susceptibility test assay

Disease Class: Staphylococcus aureus infection [ICD-11: 1B54.0] [1]

• Resistant Disease: Staphylococcus aureus infection [ICD-11: 1B54.0]
• Resistant Drug: Midecamycin
• Molecule Alteration: Expression; Acquired
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: Pseudomonas aeruginosa strain B-2099/18; 287
• Experiment for Molecule Alteration: SDS-PAGE analysis
• Experiment for Drug Resistance: Broth microdilution antifungal susceptibility test assay

Disease Class: Sepsis [ICD-11: 1G40.0] [1]

• Resistant Disease: Sepsis [ICD-11: 1G40.0]
• Resistant Drug: Midecamycin
• Molecule Alteration: Expression; Acquired
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: T7 express cells; Lung; Mus musculus (Mouse); CVCL_4314
• Experiment for Molecule Alteration: SDS-PAGE analysis
• Experiment for Drug Resistance: Broth microdilution antifungal susceptibility test assay

Disease Class: Bacillus intestinalis infection [ICD-11: 1A00-1C4Z] [1]

• Resistant Disease: Bacillus intestinalis infection [ICD-11: 1A00-1C4Z]
• Resistant Drug: Midecamycin
• Molecule Alteration: Expression; Acquired
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: Bacillus intestinalis strain T30; 1963032
• Experiment for Molecule Alteration: SDS-PAGE analysis
• Experiment for Drug Resistance: Broth microdilution antifungal susceptibility test assay

Disease Class: Bacillus intestinalis infection [ICD-11: 1A00-1C4Z] [1]

• Resistant Disease: Bacillus intestinalis infection [ICD-11: 1A00-1C4Z]
• Resistant Drug: Midecamycin
• Molecule Alteration: Missense mutation; p.Q327A
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: Bacillus intestinalis strain T30; 1963032
• Experiment for Molecule Alteration: SDS-PAGE analysis
• Experiment for Drug Resistance: Broth microdilution antifungal susceptibility test assay

Disease Class: Bacillus intestinalis infection [ICD-11: 1A00-1C4Z] [1]

• Resistant Disease: Bacillus intestinalis infection [ICD-11: 1A00-1C4Z]
• Resistant Drug: Midecamycin
• Molecule Alteration: Missense mutation; p.Q327F
• Experimental Note: Discovered Using In-vivo Testing Model
• In Vitro Model: Bacillus intestinalis strain T30; 1963032
• Experiment for Molecule Alteration: SDS-PAGE analysis
• Experiment for Drug Resistance: Broth microdilution antifungal susceptibility test assay

References

• Ref 1: Midecamycin Is Inactivated by Several Different Sugar Moieties at Its Inactivation Site .Int J Mol Sci. 2021 Nov 23;22(23):12636. doi: 10.3390/ijms222312636. 10.3390/ijms222312636